Key result
ACE D-allele carriage is linked to ~3-fold higher risk of prostate cancer vs I/I genotype.
Why the study?
The association of ACE gene insertion/deletion polymorphism with prostate cancer risk and clinical outcomes remains controversial and unstudied in North African populations.
Case-Control (n=267)
No
Odds Ratio: 2.95 (95% CI 1.26–7.09)
p-value: p=0.005
Supports ACE-prostate cancer link in observational data; hypothesis-generating and should not change practice without prospective validation.
Background Angiotensin‐converting enzyme (ACE) plays a pivotal role in several pathologies including cancers. The association of insertion/deletion (I/D) polymorphism of the ACE gene with prostate cancer (PC) risk remains controversial. We aimed to investigate for the first time, to our Knowledge, in North Africa the potential relationship between ACE I/D polymorphism with PC susceptibility and clinical outcomes of PC patients. Methods This case‐control study included 143 healthy individuals and 124 patients diagnosed with PC. Using genomic DNA, the samples were genotyped for ACE I/D polymorphism by polymerase chain reaction (PCR). Results We found that The D allele is significantly associated with an increased risk of PC and D/D + D/I genotypes were at 3 times increased risk of PC ([p = 0.005], OR = 2.95, IC 95% = 1.26–7.09) compared with I/I genotype (p = 0.003, OR = 0.3, IC 95% = 0.12–0.74). We observed an association between D/D and D/I genotypes with advanced age (≥70 years) (p = 0.014; r2 = 0.22). Furthermore, there is a significant prediction of advanced Gleason score ≥8 based on epidemiological parameters and ACE genotype (p = 0.000; R2 = 0.349), although no significant association was observed with stage and metastasis. Conclusion The ACE I/D polymorphism is likely to predispose to PC and could play a role in PC progression and aggressiveness.
No takes yet. Share an insight, caveat, or question.
Said et al. (2021) conducted a case-control in Prostate Cancer (n=267). ACE gene D/D and D/I genotypes vs. ACE gene I/I genotype was evaluated on Prostate cancer susceptibility (risk of developing prostate cancer) (OR 2.95, 95% CI 1.26-7.09, p=0.005). Carriers of the ACE gene D/D and D/I genotypes had a significantly increased risk of developing prostate cancer compared to those with the I/I genotype (OR 2.95).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: